Related Experiment Video

Updated: Sep 25, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Antibiotic use in cystic fibrosis

H W Kelly, C Lovato

    Drug Intelligence & Clinical Pharmacy
    |October 1, 1984
    PubMed

    Insights

    Chronic pulmonary infections in cystic fibrosis (CF) patients are often caused by Pseudomonas aeruginosa (PA) and Staphylococcus aureus. Current intravenous antibiotic combinations show promise, but optimal treatment strategies require further investigation.

    Area of Science:

    • Pulmonary Medicine
    • Infectious Diseases
    • Pharmacology

    Background:

    • Chronic pulmonary infections significantly increase morbidity and mortality in cystic fibrosis (CF) patients.
    • Pseudomonas aeruginosa (PA), Staphylococcus aureus, and Hemophilus influenzae are primary CF pathogens.
    • Altered pharmacokinetic variables of antibiotics are reported in CF patients.

    Purpose of the Study:

    • To review current antibiotic therapies for pulmonary infections in CF.
    • To discuss challenges in treating chronic PA infections.
    • To highlight ongoing questions regarding optimal antibiotic dosing and duration.

    Main Methods:

    • Literature review of antibiotic therapy in CF pulmonary infections.
    • Analysis of common pathogens and their sensitivities.
    • Evaluation of treatment outcomes for acute and chronic infections.

    Main Results:

    • Intravenous antibiotic combinations, particularly broad-spectrum penicillin and aminoglycosides, show efficacy for acute exacerbations.
    • Prophylactic antibiotics can be effective when pathogens are sensitive.
    • Effective oral agents for chronic PA infections are lacking, and aerosolized antibiotics offer no advantage over systemic therapy for acute issues.

    Conclusions:

    • Current intravenous antibiotic regimens are the mainstay for acute CF pulmonary exacerbations.
    • Effective management of chronic Pseudomonas aeruginosa infections remains a significant challenge.
    • Further research is needed to determine optimal antibiotic dosages, frequencies, and treatment durations for CF patients.

    More Related Videos

    Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

    Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

    Published on: September 20, 2024

    Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

    Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

    Published on: April 18, 2025

    Related Concept Videos

    Cystic Fibrosis: Pathogenesis01:23

    Cystic Fibrosis: Pathogenesis

    Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
    CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
    Cystic Fibrosis: Management01:24

    Cystic Fibrosis: Management

    Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
    Sinus disease and chronic sinusitis...
    Microbiota Modulation by Antibiotics01:21

    Microbiota Modulation by Antibiotics

    Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
    Mechanism of Antibiotic Resistance in MRSA01:25

    Mechanism of Antibiotic Resistance in MRSA

    Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
    Inhibitors of Bacterial DNA Synthesis01:28

    Inhibitors of Bacterial DNA Synthesis

    Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
    Clinical Significance of Antibiotic Resistance01:25

    Clinical Significance of Antibiotic Resistance

    Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...